Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Bacterial pulmonary infections in HIV-infected patients

INTRODUCTION

Bacterial pulmonary infections occur commonly in persons infected with the human immunodeficiency virus (HIV) [1]. The annual incidence of bacterial pneumonia in HIV-seropositive patients ranges from 5.5 to 29 per 100, compared with 0.7 to 10 per 100 in HIV-seronegative patients [2-4]. In developed countries, bacterial pathogens account for a majority of respiratory infections in HIV-infected individuals, particularly as Pneumocystis jirovecii incidence has declined profoundly in the era of highly effective antiretroviral therapy (HAART) [5,6].

RISK FACTORS FOR PNEUMONIA

Although bacterial pneumonias can occur throughout the course of HIV infection, they tend to develop more frequently in individuals with advanced immunosuppression [3,7].

Immune status — A direct relation between the CD4 count and the incidence of bacterial pneumonia was noted in a 2006 report: 4.9, 8.7, and 17.9 episodes occurred per 100 patient years with respective CD4 counts of >500, 200 to 500, and <200 cells/microL [4].

HIV infection is also a risk factor for recurrent pneumococcal pneumonia and bacteremia [8]. (See "Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia", section on 'HIV infection'.)

Based upon these observations, the Centers for Disease Control and Prevention (CDC) added recurrent bacterial pneumonia as an AIDS–defining condition in 1992 [9]. Among HIV–infected patients, injection drug users (IDU), inner city inhabitants, smokers, and persons from developing countries are at highest risk for bacterial pneumonias [2,3,10,11].

                          

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2014. | This topic last updated: Feb 27, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Hull MW, Phillips P, Montaner JS. Changing global epidemiology of pulmonary manifestations of HIV/AIDS. Chest 2008; 134:1287.
  2. Caiaffa WT, Graham NM, Vlahov D. Bacterial pneumonia in adult populations with human immunodeficiency virus (HIV) infection. Am J Epidemiol 1993; 138:909.
  3. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med 1995; 333:845.
  4. Kohli R, Lo Y, Homel P, et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis 2006; 43:90.
  5. Magnenat JL, Nicod LP, Auckenthaler R, Junod AF. Mode of presentation and diagnosis of bacterial pneumonia in human immunodeficiency virus-infected patients. Am Rev Respir Dis 1991; 144:917.
  6. Afessa B, Green W, Chiao J, Frederick W. Pulmonary complications of HIV infection: autopsy findings. Chest 1998; 113:1225.
  7. Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 1992; 267:1798.
  8. Turett GS, Blum S, Telzak EE. Recurrent pneumococcal bacteremia: risk factors and outcomes. Arch Intern Med 2001; 161:2141.
  9. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1.
  10. Polsky B, Gold JW, Whimbey E, et al. Bacterial pneumonia in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986; 104:38.
  11. Witt DJ, Craven DE, McCabe WR. Bacterial infections in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS-related complex. Am J Med 1987; 82:900.
  12. Heffernan RT, Barrett NL, Gallagher KM, et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005; 191:2038.
  13. Sullivan JH, Moore RD, Keruly JC, Chaisson RE. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med 2000; 162:64.
  14. Sogaard OS, Lohse N, Gerstoft J, et al. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study. Clin Infect Dis 2008; 47:1345.
  15. Gordin FM, Roediger MP, Girard PM, et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med 2008; 178:630.
  16. Twigg Iii HL, Weiden M, Valentine F, et al. Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects. J Infect Dis 2008; 197:109.
  17. Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165:1533.
  18. Jordano Q, Falcó V, Almirante B, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38:1623.
  19. Barry PM, Zetola N, Keruly JC, et al. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003. AIDS 2006; 20:437.
  20. Wolff AJ, O'Donnell AE. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest 2001; 120:1888.
  21. Rodriguez-Barradas MC, Goulet J, Brown S, et al. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis 2008; 46:1093.
  22. Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.
  23. Schleicher GK, Hopley MJ, Feldman C. CD4 T-lymphocyte subset counts in HIV-seropositive patients during the course of community-acquired pneumonia caused by Streptococcus pneumoniae. Clin Microbiol Infect 2004; 10:587.
  24. Morris AM, Huang L, Bacchetti P, et al. Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons. The Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 2000; 162:612.
  25. Osmond DH, Chin DP, Glassroth J, et al. Impact of bacterial pneumonia and Pneumocystis carinii pneumonia on human immunodeficiency virus disease progression. Pulmonary Complications of HIV Study Group. Clin Infect Dis 1999; 29:536.
  26. Steinhart R, Reingold AL, Taylor F, et al. Invasive Haemophilus influenzae infections in men with HIV infection. JAMA 1992; 268:3350.
  27. Casadevall A, Dobroszycki J, Small C, Pirofski LA. Haemophilus influenzae type b bacteremia in adults with AIDS and at risk for AIDS. Am J Med 1992; 92:587.
  28. Schlamm HT, Yancovitz SR. Haemophilus influenzae pneumonia in young adults with AIDS, ARC, or risk of AIDS. Am J Med 1989; 86:11.
  29. Levine SJ, White DA, Fels AO. The incidence and significance of Staphylococcus aureus in respiratory cultures from patients infected with the human immunodeficiency virus. Am Rev Respir Dis 1990; 141:89.
  30. Javaly K, Horowitz HW, Wormser GP. Nocardiosis in patients with human immunodeficiency virus infection. Report of 2 cases and review of the literature. Medicine (Baltimore) 1992; 71:128.
  31. Doebbeling BN, Feilmeier ML, Herwaldt LA. Pertussis in an adult man infected with the human immunodeficiency virus. J Infect Dis 1990; 161:1296.
  32. Cury JD, Harrington PT, Hosein IK. Successful medical therapy of Rhodococcus equi pneumonia in a patient with HIV infection. Chest 1992; 102:1619.
  33. Drabick JJ, Gasser RA Jr, Saunders NB, et al. Pasteurella multocida pneumonia in a man with AIDS and nontraumatic feline exposure. Chest 1993; 103:7.
  34. Baron AD, Hollander H. Pseudomonas aeruginosa bronchopulmonary infection in late human immunodeficiency virus disease. Am Rev Respir Dis 1993; 148:992.
  35. Fichtenbaum CJ, Woeltje KF, Powderly WG. Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: a case-control study. Clin Infect Dis 1994; 19:417.
  36. Benito N, Rañó A, Moreno A, et al. Pulmonary infiltrates in HIV-infected patients in the highly active antiretroviral therapy era in Spain. J Acquir Immune Defic Syndr 2001; 27:35.
  37. Rimland D, Navin TR, Lennox JL, et al. Prospective study of etiologic agents of community-acquired pneumonia in patients with HIV infection. AIDS 2002; 16:85.
  38. Park DR, Sherbin VL, Goodman MS, et al. The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. J Infect Dis 2001; 184:268.
  39. Menéndez R, Cordero PJ, Santos M, et al. Pulmonary infection with Nocardia species: a report of 10 cases and review. Eur Respir J 1997; 10:1542.
  40. Kyaw MH, Rose CE Jr, Fry AM, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 2005; 192:377.
  41. Gill CJ, Mwanakasale V, Fox MP, et al. Impact of human immunodeficiency virus infection on Streptococcus pneumoniae colonization and seroepidemiology among Zambian women. J Infect Dis 2008; 197:1000.
  42. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359:753.
  43. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40:100.
  44. Vidal F, Mensa J, Martínez JA, et al. Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 1999; 18:473.
  45. Sorvillo F, Beall G, Turner PA, et al. Incidence and determinants of Pseudomonas aeruginosa infection among persons with HIV: association with hospital exposure. Am J Infect Control 2001; 29:79.
  46. Allen SH, Brennan-Benson P, Nelson M, et al. Pneumonia due to antibiotic resistant Streptococcus pneumoniae and Pseudomonas aeruginosa in the HAART era. Postgrad Med J 2003; 79:691.
  47. Lane HC, Masur H, Edgar LC, et al. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983; 309:453.
  48. Ellis M, Gupta S, Galant S, et al. Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation. J Infect Dis 1988; 158:1268.
  49. Parkin JM, Helbert M, Hughes CL, Pinching AJ. Immunoglobulin G subclass deficiency and susceptibility to pyogenic infections in patients with AIDS-related complex and AIDS. AIDS 1989; 3:37.
  50. Moja P, Jalil A, Quesnel A, et al. Humoral immune response within the lung in HIV-1 infection. Clin Exp Immunol 1997; 110:341.
  51. Wewers MD, Diaz PT, Wewers ME, et al. Cigarette smoking in HIV infection induces a suppressive inflammatory environment in the lung. Am J Respir Crit Care Med 1998; 158:1543.
  52. Takahashi H, Oishi K, Yoshimine H, et al. Decreased serum opsonic activity against Streptococcus pneumoniae in human immunodeficiency virus-infected Ugandan adults. Clin Infect Dis 2003; 37:1534.
  53. Eagan R, Twigg HL 3rd, French N, et al. Lung fluid immunoglobulin from HIV-infected subjects has impaired opsonic function against pneumococci. Clin Infect Dis 2007; 44:1632.
  54. Murray JF, Felton CP, Garay SM, et al. Pulmonary complications of the acquired immunodeficiency syndrome. Report of a National Heart, Lung, and Blood Institute workshop. N Engl J Med 1984; 310:1682.
  55. Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992; 117:314.
  56. Chaisson RE. Bacterial pneumonia in patients with human immunodeficiency virus infection. Semin Respir Infect 1989; 4:133.
  57. Gerberding JL, Drieger J, Sand MA. Recurrent bacteremic infection with S. pneumoniae in patients with AIDS virus (AV) infection. Program and abstracts of the Twenty–sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. American Society of Microbiology 1986, p. 177.
  58. Pesola GR, Charles A. Pneumococcal bacteremia with pneumonia. Mortality in acquired immunodeficiency syndrome. Chest 1992; 101:150.
  59. Chechani V, Allam AA, Smith PR, et al. Bronchitis mimicking opportunistic lung infection in patients with human immunodeficiency virus infection/AIDS. N Y State J Med 1992; 92:297.
  60. Verghese A, al-Samman M, Nabhan D, et al. Bacterial bronchitis and bronchiectasis in human immunodeficiency virus infection. Arch Intern Med 1994; 154:2086.
  61. Valor RR, Polnitsky CA, Tanis DJ, Sherter CB. Bacterial tracheitis with upper airway obstruction in a patient with the acquired immunodeficiency syndrome. Am Rev Respir Dis 1992; 146:1598.
  62. Torres-Tortosa M, Arrizabalaga J, Villanueva JL, et al. Prognosis and clinical evaluation of infection caused by Rhodococcus equi in HIV-infected patients: a multicenter study of 67 cases. Chest 2003; 123:1970.
  63. Nyamande K, Lalloo UG, Vawda F. Comparison of plain chest radiography and high-resolution CT in human immunodeficiency virus infected patients with community-acquired pneumonia: a sub-Saharan Africa study. Br J Radiol 2007; 80:302.
  64. Selwyn PA, Pumerantz AS, Durante A, et al. Clinical predictors of Pneumocystis carinii pneumonia, bacterial pneumonia and tuberculosis in HIV-infected patients. AIDS 1998; 12:885.
  65. Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003; 37:1448.
  66. Castillo EM, Rickman LS, Brodine SK, et al. Streptococcus pneumoniae: bacteremia in an era of penicillin resistance. Am J Infect Control 2000; 28:239.
  67. Mayer HB, Rose DN, Cohen S, et al. The effect of Pneumocystis carinii pneumonia prophylaxis regimens on the incidence of bacterial infections in HIV-infected patients. AIDS 1993; 7:1687.
  68. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992; 327:1842.
  69. 2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus (US consensus guidelines) www.aidsinfo.nih.gov (Accessed on September 18, 2005).
  70. Eigenmann C, Flepp M, Bernasconi E, et al. Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis. Clin Infect Dis 2003; 36:917.
  71. Havlir DV, Dubé MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 1996; 335:392.
  72. Crothers K, Beard CB, Turner J, et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. AIDS 2005; 19:801.